InvestorsHub Logo
Followers 2
Posts 253
Boards Moderated 0
Alias Born 06/04/2007

Re: None

Tuesday, 08/27/2013 12:08:08 AM

Tuesday, August 27, 2013 12:08:08 AM

Post# of 1874
2nd Quarter Results Posted -

http://finance.yahoo.com/news/oncolytics-biotech-r-inc-announces-103000358.html

08/01/2013 06:30:00
Oncolytics Biotech(R) Inc. Announces Second Quarter 2013 Results
CALGARY, Aug. 1, 2013 /CNW/ - Oncolytics Biotech Inc. (TSX:ONC) (NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced its financial results and operational highlights for the quarter ended June 30, 2013.

"We are pleased to continue to demonstrate positive clinical results with the recent announcement of a disease control rate of 71.5% in our metastatic melanoma study," said Dr. Brad Thompson, President and CEO of Oncolytics. "We are ready to commence the data analysis of stage 1 of our head and neck trial as soon as we can and we continue to enroll patients in our six other randomized trials."

Selected Highlights

Clinical Trial Results

Reached the stage 1 endpoint in stage 1 of the U.S. Phase 2 clinical trial in patients with metastatic melanoma (REO 020) after only 14 patients were enrolled. The primary objective of this Phase 2 trial was to assess the antitumour effect of the treatment regimen in the study population in terms of objective response rates. The secondary objectives were to assess progression-free survival and overall survival for the treatment regimen; the disease control rate (complete response (CR) plus partial response (PR) plus stable disease (SD)) and duration, and to assess the safety and tolerability of the treatment regimen in the study population. Three of the 14 patients exhibited a PR, and an additional seven patients had SD for a disease control rate of 71.5%.
Clinical Trial Program

Preparing to commence the data analysis of stage 1 of the randomized head and neck clinical study (REO 018) once sufficient patient events have occurred; and
Financial

Exited the second quarter with over $36.1 million of cash, cash equivalents and short-term investments.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONCY News